SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nodality, Inc., today announced publication of data in the journal PLOS ONE detailing the clinical validation of the Company’s Single Cell Network Profiling (SCNP)-based diagnostic classifier for prediction of response to standard induction therapy (cytarabine (Ara-C)-based chemotherapy) in elderly patients with Acute Myeloid Leukemia (AML). SCNP is a multiparametric flow cytometry-based platform that provides robust, human cell-based translational
| < Prev | Next > |
|---|
